ASND Overview

Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.

Wall Street analysts forecast ASND stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ASND is277.08 USD with a low forecast of 240.00 USD and a high forecast of 342.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Ascendis Pharma A/S revenue for the last quarter amounts to 247.50M USD, increased 42.31

Ascendis Pharma A/S. EPS for the last quarter amounts to -0.55 USD, decreased -14.06

Ascendis Pharma A/S (ASND) has 1189 emplpoyees as of April 21 2026.

Today ASND has the market capitalization of 15.21B USD.